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Abstract
Background Metastatic prostate cancer has a 30% 5-year survival rate despite recent therapeutic advances. There is a need 
to improve the clinical understanding and treatment of this disease, particularly in the real-world setting and among patients 
who are under-represented in clinical trials.
Objective We aimed to evaluate the characteristics and clinical outcomes of patients who received their first treatment for 
metastatic castration-resistant prostate cancer (mCRPC) in routine clinical practice, independent of treatment used, including 
subgroups with baseline cardiac disease, diabetes mellitus, or visceral metastases.
Patients and methods Prospective, noninterventional analysis of patient record data in the multicenter Prostate Cancer Reg-
istry (PCR) of men with mCRPC. The data were collected in 16 countries with the aim of recruiting more than 3000 patients 
between 2013 and 2016. The study end date was 9 July 2018. Data evaluated included baseline characteristics, treatment 
exposure, and efficacy outcomes [overall survival (OS) and time to progression (TTP)] of patients treated with abiraterone 
acetate plus prednisone or prednisolone (collectively, “abiraterone”), enzalutamide, or docetaxel. Descriptive outcomes are 
reported from the overall patient population and subgroups of patients with baseline cardiovascular disease, diabetes mel-
litus, or visceral metastases. The treatment effects for time to progression were compared for the overall patient population.
Results The study enrollment period lasted 2.5 years, and each patient was followed for a maximum of 3 years. A total of 
1874 patients in the PCR had not received previous mCRPC treatment at baseline, although they had received androgen-
deprivation therapy. Prevalent co-morbidities included cardiovascular disease in 65.4% and diabetes mellitus in 17.4% of 
patients. Baseline characteristics suggested that patients with more advanced disease received docetaxel treatment. In the 
overall patient population, the median time to progression with abiraterone, enzalutamide, and docetaxel as first-line mCRPC 
therapy was 9.6, 10.3, and 7.6 months, respectively, and median OS was 27.1, 27.1, and 27.9 months, respectively. Outcomes 
in the subgroups of patients with cardiovascular disease or diabetes mellitus were similar to those of the whole population in 
the analysis. As expected, patients with visceral metastases had shorter TTP and OS than patients in the overall population.
Conclusions This analysis shows, for the first time, the effectiveness in parallel of first-line abiraterone, enzalutamide, and 
docetaxel in mCRPC, including in patients with co-morbidities such as cardiovascular disease or diabetes mellitus or in 
patients with visceral metastases. These real-world findings from the PCR provide meaningful information to help manage 
mCRPC, particularly in patients under-represented in clinical studies.
Trial Registration ClinicalTrials.gov identifier NCT02236637; registered September 2014.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1152 3-020-00720 -2) contains 
supplementary material, which is available to authorized users.
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Key Points 
The Prostate Cancer Registry collected real-world data 
on the clinical characteristics, management, and out-
comes of more than 3000 men with metastatic castration-
resistant prostate cancer (mCRPC) from 2013–2016.
This study found that the efficacy of three major first-
line treatments for mCRPC (abiraterone, enzalutamide, 
and docetaxel) was similar between subpopulations of 
patients with co-morbidities and the wider patient popu-
lation.
These real-world data provide information on long-term 
outcomes for patients with metastatic castration-resistant 
prostate cancer.
1  Background
Prostate cancer is the second most common cancer and fifth 
leading cause of death from cancer in men [1]. Worldwide, 
an estimated 1.1 million men were diagnosed with prostate 
cancer in 2012, representing 15% of all cancers diagnosed in 
men, and the disease caused 307,000 deaths [1]. In Europe, 
450,000 new cases of prostate cancer were diagnosed in 
2018, and 107,000 deaths were reported [2]. Prostate cancer 
survival rates vary widely according to stage. Outcomes for 
localized prostate cancer are very good, owing to effective 
radical surgery or radiation therapy [3]. However, the mor-
tality rate among men in whom the disease has progressed 
to metastatic prostate cancer is substantial. Although several 
options for treatment of metastatic castration-resistant pros-
tate cancer (mCRPC) (abiraterone, enzalutamide, cabazi-
taxel, radium-223, and sipuleucel-T) have shown a survival 
benefit in phase 3 trials, evidence for optimal sequences or 
combinations is lacking [4–6]. Expert opinion is helpful for 
treatment decisions in routine clinical practice [7]; however, 
there is a substantial need to improve the understanding and 
management of this disease—in particular, to avoid progres-
sion to disease states in which mortality rates are high and to 
assess patients outside of a clinical trial setting.
The Prostate Cancer Registry (PCR) (NCT02236637) 
was initiated in 2013 to collect real-world data on mCRPC 
treatments. This is the first and largest prospective, interna-
tional, observational study of patients with mCRPC. The 
PCR aims to document the characteristics, management, 
and outcomes of more than 3000 men in routine clinical 
practice, independent of treatment used. Enrollment took 
place between June 2013 and March 2016, when unprece-
dented progress was being made in the treatment of mCRPC 
in Europe. The PCR provided the opportunity to capture a 
wealth of data on all mCRPC treatments from this critical 
period in a wide range of countries and patients, including 
groups under-represented in clinical research. Thus, the PCR 
contains important data reflecting clinical practice in these 
challenging subgroups of patients with mCRPC, for whom 
data on which to base treatment decisions are often lacking.
This analysis of data in the PCR focuses on the char-
acteristics and clinical outcomes of patients who received 
their first treatment for mCRPC in routine clinical practice 
including subgroups with baseline cardiac disease, diabetes 
mellitus, or visceral metastases. Specifically, baseline patient 
characteristics, treatment exposure, overall survival (OS), 
and time to progression were evaluated.
2  Methods
2.1  Aim, Study Design, and Setting
This prospective, noninterventional analysis of patient 
record data from the multicenter PCR of men with mCRPC 
was conducted to gain a greater understanding of real-world 
outcomes in a broad group of patients treated for mCRPC 
to optimize future treatment of patients with this disease. 
We focused on the characteristics and clinical outcomes of 
patients, including subgroups with baseline cardiac disease, 
diabetes mellitus, or visceral metastases, who received their 
first treatment for mCRPC during participation in the PCR. 
The data for the PCR were collected at 199 centers special-
izing in the treatment of prostate cancer by both oncologists 
and urologists in a range of settings (including hospitals, 
private clinics, outpatient departments, and universities) in 
16 countries: Austria, Belgium, France, Germany, Israel, 
Italy, Luxembourg, Poland, Portugal, Russia, Slovenia, 
Spain, Sweden, Switzerland, Turkey, and the UK. Patient 
enrollment took place between 2013 and 2016. At the start 
of the PCR, abiraterone acetate and enzalutamide were not 
routinely available in the mCRPC setting in all 16 coun-
tries. The study duration was 5.5 years, with a maximum 
patient follow-up of 3 years, and was designed specifically 
to include more than one line of therapy where applicable. 
The study end date was 9 July 2018.
2.2  Patients
Men aged ≥ 18 years with a histologically or cytologically 
confirmed diagnosis of prostate adenocarcinoma with 
mCRPC (disease progression despite testosterone < 50 ng/dL 
and/or androgen deprivation therapy and/or history of orchi-
ectomy), enrolled at any time after diagnosis, under surveil-
lance according to routine clinical practice, or who initiated 
a systemic treatment for mCRPC (as required) following 
baseline data collection at enrollment, were eligible. The 
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PCR included patients treated with abiraterone acetate plus 
prednisone or prednisolone (collectively, “abiraterone”), 
enzalutamide, docetaxel, other chemotherapy, and 
radium-223. Only treatment groups with adequate num-
bers of patients (> 50) for reliable analysis were included. 
Patients treated with other chemotherapy or radium-223 
were excluded because the numbers were too low.
2.3  Variables and Data Measurement
Treatment outcomes were duration of initial therapy and rea-
sons for stopping initial mCRPC therapy. Appropriate treat-
ment gaps for classifying subsequent therapy were 30 days 
for abiraterone or enzalutamide and 60 days for docetaxel, 
which included any prolonged, temporary treatment dis-
continuation. Efficacy outcomes were OS at 3 years after 
enrollment and time to progression. Criteria for disease pro-
gression on treatment (date of recording progression/assess-
ment) were met if: (1) there was evidence of radiographic 
progression by investigator’s assessment (Prostate Cancer 
Working Group 2 and Response Evaluation Criteria In Solid 
Tumors guidelines were recommended by the protocol); (2) 
there was evidence of clinical progression by investigator’s 
assessment (date of the patient visit); (3) first-line mCRPC 
treatment was stopped because of progression (date treat-
ment stopped); or (4) new mCRPC treatment was started 
because of progression (date new treatment began). The 
treatment effects for time to progression with the therapies 
of interest were compared for the entire analysis popula-
tion. We compared treatment outcomes in the whole analysis 
population with those in subgroups of patients with base-
line cardiovascular disease requiring treatment (including 
at least one of the following co-morbidities: hypertension, 
angina pectoris, history of myocardial infarction, arrhyth-
mia, thromboembolic disease, transient ischemic attack, cer-
ebrovascular accident, and/or other cardiovascular event), 
diabetes mellitus, or visceral metastases (defined as lesions 
in the liver and/or lung). These patient subgroups are typi-
cally under-represented in clinical studies. Adverse events 
were collected only for those patients receiving abiraterone, 
as a regulatory requirement.
We used observational methodology to capture data. 
The treating physician made treatment decisions at his or 
her discretion, per routine clinical practice, and only data 
available from clinical practice were collected. We collected 
prior disease history and management data at study inclusion 
and clinical data at study inclusion and prospectively every 
3 months during routine follow-up (at least every 3 months 
per protocol) over the 3-year study period, with clinical-
trial levels of monitoring quality (see Supplementary Fig. 
S1). Because docetaxel is administered through a maximum 
number of cycles (typically 6–10 cycles as appropriate), out-
comes influenced by duration of docetaxel treatment should 
not be compared with those of abiraterone or enzalutamide. 
Cause of death data were not collected.
2.4  Bias
To ensure a patient population representative of that seen in 
clinical practice and to reduce selection bias, the protocol 
stated that all consecutive patients meeting the eligibility 
criteria at a participating site and who agreed to participate 
according to local regulations were enrolled in the PCR, 
irrespective of their treatment.
2.5  Study Size
Of more than 3000 men included in the PCR, data from 
patients who were being treated with abiraterone, enzalu-
tamide, or docetaxel as first-line mCRPC therapy and who 
had not received previous systemic mCRPC treatment were 
included in this analysis. The PCR was designed to gener-
ate data for informative purposes. Thus, this sample size 
was determined by pragmatic considerations, to provide data 
from a large population that is representative of patients with 
mCRPC in the Europe/Middle East region.
2.6  Statistical Methods
We only used descriptive statistics to present observed data 
from routine clinical practice. To manage confounding, we 
used propensity score methods for the comparative effec-
tiveness analyses. We did not apply missing data imputa-
tion methods; thus, there were no sensitivity analyses, and 




At the end of study, 3003 patients were evaluated, 1874 
(62.4%) of whom had received no previous mCRPC treat-
ment; of these, 1654 (88.3%) started a treatment documented 
in the PCR (abiraterone, enzalutamide, docetaxel, other 
chemotherapy, radium-223, trial medication). Abiraterone, 
enzalutamide, or docetaxel as first-line mCRPC therapy was 
received by 754, 227, and 602 patients, respectively, with a 
median follow-up of 18.6 months. The number of patients 
and study flow are presented in the Supplementary Material 
(Fig S2).
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3.2  Overall and First‑Line mCRPC Treatment 
Population
3.2.1  Baseline Characteristics
Patient demographics and disease and biological charac-
teristics at study inclusion are shown in Table 1. Patients 
treated with docetaxel were younger than those treated with 
abiraterone or enzalutamide (median age [range]: 69 [44–88] 
vs. 76 [43–98] and 76 [53–91] years, respectively) and had a 
shorter median (range) time from initial diagnosis to study 
inclusion (2.6 [0–22] years vs. 5.0 [0–29] years and 4.5 
[0–24] years, respectively). At diagnosis, de novo metas-
tases were reported in 35.0% of patients in the abiraterone 
group compared with 42.3% in the enzalutamide group and 
50.1% in the docetaxel group. Median (range) time from 
initial to metastatic diagnosis was 2.5 (0–29), 0.9 (0–21), 
and 0.1 (0–21) months for the abiraterone, enzalutamide, 
and docetaxel groups, respectively. In addition, a Gleason 
score of 8–10 was reported in 51.0%, 60.6%, and 58.4% of 
patients in the abiraterone, enzalutamide, and docetaxel 
groups, respectively.
Details regarding treatment history at study inclusion are 
presented in Table 2. Overall, 10.1% and 21.3% of patients 
had undergone either radical prostatectomy or prostate radi-
otherapy, respectively, since initial diagnosis (abiraterone, 
11.8% and 23.1%; enzalutamide, 9.5% and 23.3%; docetaxel, 
9.5% and 23.3%; respectively) and 94.7% had received at 
least one prior systemic anticancer therapy since diag-
nosis (95.1%, 93.8%, and 94.2% for patients treated with 
abiraterone, enzalutamide, and docetaxel, respectively). 
Orchiectomy had been performed in 4.6%, 7.3%, and 5.3% 
of patients, respectively.
3.2.2  Treatment Exposure
The median (95% confidence interval [CI]) duration of 
treatment according to the Kaplan–Meier analysis was 
11.2 (9.8–12.2) months with abiraterone, 13.0 (10.4–15.9) 
months with enzalutamide, and 4.8 (4.4–5.0) months with 
docetaxel (Supplementary Table S1). In the abiraterone, 
enzalutamide, and docetaxel groups, the most common rea-
son for stopping treatment was disease progression (72.8%, 
67.3%, and 27.0% of patients) (Supplementary Table S2). 
The proportion of patients who discontinued treatment 
because of toxicity was 7.1%, 13.5%, and 14.2% in these 
groups, and death during treatment was reported in 7.2%, 
11.1%, and 3.8% of patients, respectively (Supplementary 
Table S2). In this first-line mCRPC treatment population, 
48.7%, 43.6%, and 70.8%, of abiraterone-, enzalutamide-, 
and docetaxel-treated patients, respectively, went on to 
receive a subsequent treatment; the most common switch 
was from abiraterone to docetaxel followed by enzalutamide 
to docetaxel (Table 3).
3.2.3  Efficacy Outcomes
Kaplan–Meier estimates showed that the median (95% confi-
dence interval (CI)) time to progression was 9.6 (8.4–10.8), 
10.3 (8.9–13.0), and 7.6 (7.0–8.0) months with abiraterone, 
enzalutamide, and docetaxel, respectively (Fig. 1a, Table 4). 
The treatment effects for time to progression comparing 
abiraterone versus docetaxel and enzalutamide versus doc-
etaxel were statistically significant (all p < 0.0001; hazard 
ratio < 1.0), while those comparing abiraterone versus enza-
lutamide were not significant (all p > 0.5; hazard ratios > 1.0) 
(Table 5). The median (95% CI) OS was 27.1 (25.3–28.9), 
27.1 (21.8–32.7), and 27.9 (25.6–31.5) months in the 
abiraterone, enzalutamide, and docetaxel groups, respec-
tively (Fig. 2a, Table 6). None of the differences between 
treatment groups for OS were significant (Table 7).
3.3  Patients with Cardiovascular Disease
3.3.1  Baseline Characteristics
At baseline, cardiovascular disease was reported in 504 
(66.8%), 161 (70.9%), and 351 (58.3%) patients in the 
abiraterone, enzalutamide, and docetaxel, groups, respec-
tively; the most common cardiovascular co-morbidity was 
hypertension in all three treatment groups (54.5%, 56.8%, 
and 48.0%, respectively), followed by specific cardiovas-
cular co-morbidities of arrhythmia and history of myocar-
dial infarction (Table 1). This cardiovascular disease group 
also had important concomitant co-morbidities for patients 
receiving abiraterone, enzalutamide, and docetaxel: diabetes 
mellitus (types 1 and 2) was reported in 101 (20.0%), 36 
(22.4%), and 84 (23.9%) patients; respiratory co-morbidi-
ties were reported in 46 (9.1%), 23 (14.3%), and 38 (10.8%) 
patients; and neurologic co-morbidities were reported in 52 
(10.3%), 17 (10.6%), and 37 (10.5%) patients, respectively 
(Supplementary Table S3A).
Patients treated with abiraterone had a median (range) 
time from initial prostate cancer diagnosis to study inclu-
sion of 5.3 (0–29) years versus 4.9 (0–21) and 3.1 (0–22) 
years for the enzalutamide and docetaxel groups, respec-
tively. Median (range) age at baseline was 77 (50–94), 77 
(59–91), and 71 (47–88) years, respectively (Supplementary 
Table S3A), which was older than the ages reported in recent 
registration studies [8, 9]. At diagnosis, 49.8%, 59.0%, and 
56.6% of patients in the abiraterone, enzalutamide, and doc-
etaxel groups, respectively, had a Gleason score of 8–10 
(Supplementary Table S3A). Details regarding treatment 
history at study inclusion are presented in Supplementary 
Table S3B.
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Table 1  Patient demographics and disease and biological characteristics at study inclusion in the first-line mCRPC treatment population
Characteristic Patients who had not received 
previous mCRPC treatment at 
baseline N = 1874
First-line treatment with
Abiraterone N = 754 Enzalutamide N = 227 Docetaxel N = 602
Age,
 Mean (SD), years 73.1 (8.58) 75.3 (8.20) 74.9 (7.87) 68.8 (7.70)
 Median (range), years 74.0 (43–98) 76.0 (43–98) 76.0 (53–91) 69.0 (44–88)
Age group, n (%)
 < 65 years 314 (16.8) 81 (10.7) 24 (10.6) 173 (28.7)
 65–74 years 683 (36.4) 228 (30.2) 75 (33.0) 280 (46.5)
 ≥ 75 years 877 (46.8) 445 (59.0) 128 (56.4) 149 (24.8)
Geographic distribution, n (%)
 N 1874 (100.0) 754 (100.0) 227 (100.0) 602 (100.0)
 Austria 12 (0.6) 2 (0.2) 2 (0.9) 2 (0.3)
 Belgium 129 (6.9) 60 (8.0) 25 (11.0) 28 (4.7)
 France 209 (11.2) 116 (15.4) 27 (11.9) 53 (8.8)
 Germany 240 (12.8) 128 (17.0) 19 (8.4) 61 (10.1)
 Israel 18 (1.0) 11 (1.5) 0 3 (0.5)
 Italy 238 (12.7) 157 (20.8) 2 (0.9) 70 (11.6)
 Luxembourg 8 (0.4) 1 (0.1) 0 6 (1.0)
 Poland 163 (78.7) 1 (0.1) 2 (0.9) 122 (20.3)
 Portugal 78 (4.2) 21 (2.8) 2 (0.9) 43 (7.1)
 Russia 79 (4.2) 16 (2.1) 2 (0.9) 27 (4.5)
 Slovenia 22 (1.2) 14 (1.9) 2 (0.9) 1 (0.2)
 Spain 141 (7.5) 85 (11.3) 17 (7.5) 24 (4.0)
 Sweden 149 (8.0) 18 (2.4) 47 (20.7) 38 (6.3)
 Switzerland 14 (0.8) 6 (0.8) 1 (0.4) 7 (1.2)
 Turkey 61 (3.3) 10 (1.3) 0 47 (7.8)
 United Kingdom 313 (16.7) 108 (14.3) 79 (34.8) 70 (11.6)
ECOG performance status, n (%)
 N 1732 715 187 555
 0 746 (43.1) 340 (47.6) 99 (52.9) 211 (38.0)
 1 797 (46.0) 318 (44.5) 69 (36.9) 293 (52.8)
  ≥ 2 189 (10.9) 57 (8.0) 19 (10.2) 51 (9.2)
Gleason score at initial diagnosis, n 
(%)
 N 1713 674 208 574
  ≤ 6 216 (12.6) 100 (14.8) 25 (12.0) 61 (10.6)
 7 548 (32.0) 230 (34.1) 57 (27.4) 178 (31.0)
 8–10 949 (55.4) 344 (51.0) 126 (60.6) 335 (58.4)
M stage at initial diagnosis, n (%)
 N 1830 732 222 591
 Mx 353 (19.3) 161 (22.0) 40 (18.0) 100 (16.9)
 M0 682 (37.3) 315 (43.0) 88 (39.6) 195 (33.0)
 M1, M1a, M1b, M1c 795 (43.4) 256 (35.0) 94 (42.3) 296 (50.1)
Time from initial prostate cancer 
diagnosis to start of the study
 N 1874 754 227 602
 Median years (range) 3.8 (0–29) 5.0 (0–29) 4.5 (0–24) 2.6 (0–22)
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Table 1  (continued)
Characteristic Patients who had not received 
previous mCRPC treatment at 
baseline N = 1874
First-line treatment with
Abiraterone N = 754 Enzalutamide N = 227 Docetaxel N = 602
Presence of bone metastases 
(baseline), n (%)
 N 1396 550 184 451
 Any 1253 (89.8) 548 (99.6) 164 (89.1) 405 (89.8)
  ≥ 5 548 (39.3) 203 (36.9) 60 (32.6) 192 (42.6)
Visceral metastases (baseline), n (%)
 N 1484 612 163 517
 Liver only 69 (4.6) 13 (2.1) 9 (5.5) 39 (7.5)
 Lung only 96 (6.5) 39 (6.4) 7 (4.3) 40 (7.7)
 Liver and lung 17 (1.1) 7 (1.1) 0 9 (1.7)
Biological parameters
 PSA, ng/mL
 N 1833 733 226 588
 Mean (SD) 143.66 (462.496) 125.54 (488.412) 79.82 (173.516) 181.05 (510.264)
Lactic acid dehydrogenase, U/L
 N 732 331 77 242
 Mean (SD) 344.5 (296.75) 330.3 (281.58) 283.5 (204.28) 367.1 (320.45)
Hemoglobin, g/dL
 N 1618 651 199 530
 Mean (SD) 12.6 (1.67) 12.7 (1.63) 12.9 (1.43) 12.5 (1.73)
Alkaline phosphatase, U/L
 N 1365 575 191 414
 Mean (SD) 209.6 (341.29) 192.1 (282.84) 181.8 (473.49) 223.7 (297.86)
Co-morbidities requiring treatment, n (%)
 Any 1367 (72.9) 566 (75.1) 176 (77.5) 398 (66.1)
 Cardiovascular 1221 (65.2) 504 (66.8) 161 (70.9) 351 (58.3)
  Hypertension 1002 (53.5) 411 (54.5) 129 (56.8) 289 (48.0)
  Angina pectoris 115 (6.1) 34 (4.5) 12 (5.3) 35 (5.8)
  Myocardial infarction 133 (7.1) 48 (6.4) 21 (9.3) 32 (5.3)
  Arrhythmia 154 (8.2) 62 (8.2) 22 (9.7) 41 (6.8)
  Thromboembolic disease 55 (2.9) 21 (2.8) 8 (3.5) 18 (3.0)
  Cerebrovascular accident 48 (2.6) 19 (2.5) 3 (1.3) 17 (2.8)
  Transient ischemic attack 34 (1.8) 14 (1.9) 5 (2.2) 9 (1.5)
  Other cardiovascular 300 (16.0) 139 (18.4) 39 (17.2) 80 (13.3)
Respiratory 160 (8.5) 60 (8.0) 27 (11.9) 48 (8.0)
 Chronic obstructive pulmonary 
disease
105 (5.6) 41 (5.4) 16 (7.0) 29 (4.8)
 Other respiratory 60 (3.2) 20 (2.7) 12 (5.3) 19 (3.2)
Renal 143 (7.6) 52 (6.9) 24 (10.6) 42 (7.0)
 Chronic renal disease 82 (4.4) 31 (4.1) 16 (7.0) 21 (3.5)
 Other renal 62 (3.3) 21 (2.8) 8 (3.5) 21 (3.5)
Hepatic 31 (1.7) 17 (2.3) 3 (1.3) 8 (1.3)
 Chronic hepatic disease 17 (0.9) 9 (1.2) 3 (1.3) 4 (0.7)
 Other hepatic 14 (0.7) 8 (1.1) 0 4 (0.7)
Neurologic 157 (8.4) 66 (8.8) 17 (7.5) 41 (6.8)
 Peripheral sensory impairment 8 (0.4) 2 (0.3) 0 5 (0.8)
 Memory impairment 14 (0.7) 5 (0.7) 4 (1.8) 2 (0.3)
 Cognitive disorder 12 (0.6) 4 (0.5) 2 (0.9) 1 (0.2)
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3.3.2  Treatment Exposure
Median (95% CI) treatment durations were 11.1 (9.5–12.7) 
months with abiraterone, 12.7 (9.1–15.3) months with 
enzalutamide, and 4.6 (4.3–5.0) months with docetaxel 
for typically 6–10 cycles (Supplementary Table S1); these 
are similar to durations observed in the equivalent overall 
patient population treatment groups, in which docetaxel 
exposure was shorter than abiraterone and enzalutamide 
exposures. In the abiraterone, enzalutamide, and docetaxel 
Table 1  (continued)
Characteristic Patients who had not received 
previous mCRPC treatment at 
baseline N = 1874
First-line treatment with
Abiraterone N = 754 Enzalutamide N = 227 Docetaxel N = 602
 Convulsion 5 (0.3) 3 (0.4) 0 0
 Other neurologic 54 (2.9) 27 (3.6) 4 (1.8) 10 (1.7)
Infections 11 (0.6) 6 (0.8) 3 (1.3) 1 (0.2)
 Other infection 11 (0.6) 6 (0.8) 3 (1.3) 1 (0.2)
Diabetes mellitus 307 (16.4) 121 (16.0) 47 (20.7) 100 (16.6)
 Type 2 235 (12.5) 87 (11.5) 36 (15.9) 82 (13.6)
 Type 1 72 (3.8) 34 (4.5) 11 (4.8) 18 (3.0)
Investigations
 Hypercholesterolemia 276 (14.7) 122 (16.2) 48 (21.1) 62 (10.3)
ECOG Eastern Cooperative Oncology Group, M metastatic status, mCRPC metastatic castration-resistant prostate cancer, N number of evaluable 
patients for each specific parameter, PSA prostate-specific antigen, SD standard deviation
Table 2  Treatment history at study inclusion in the first-line mCRPC treatment population
GnRH gonadotropin-releasing hormone, mCRPC metastatic castration-resistant prostate cancer
Prior treatment, n (%) Patients who had not received previous 
mCRPC treatment at baseline n = 1874
First-line treatment with
Abiraterone n = 754 Enzalutamide n = 227 Docetaxel n = 602
Orchiectomy since initial diagnosis 123 (6.6) 35 (4.6) 12 (5.3) 44 (7.3)
Radical prostatectomy/prostate-specific  
radiotherapy since initial diagnosis
 Both radical prostatectomy and 
prostate-specific radiotherapy
160 (8.5) 79 (10.5) 18 (7.9) 52 (8.6)
 Radical prostatectomy only 190 (10.1) 89 (11.8) 21 (9.3) 57 (9.5)
 Prostate-specific radiotherapy only 399 (21.3) 174 (23.1) 46 (20.3) 140 (23.3)
 None 1125 (60.0) 412 (54.6) 142 (62.6) 353 (58.6)
Prior systemic anticancer therapy
 Any 1774 (94.7) 718 (95.2) 213 (93.8) 567 (94.2)
 Endocrine therapy 1755 (93.6) 710 (94.2) 211 (93.0) 562 (93.4)
  Antiandrogen 1569 (83.7) 646 (85.7) 188 (82.8) 506 (84.1)
  GnRH agonist 1280 (68.3) 474 (62.9) 211 (93.0) 434 (72.1)
  Steroids 194 (10.4) 76 (10.1) 22 (9.7) 75 (12.5)
  GnRH antagonist 127 (6.8) 64 (8.5) 9 (4.0) 39 (6.5)
  Estrogens and derivatives 53 (2.8) 28 (3.7) 7 (3.1) 5 (0.8)
  Adrenal synthesis inhibitors 14 (0.7) 6 (0.8) 0 (0) 7 (1.2)
  Other 6 (0.3) 0 (0) 3 (1.3) 2 (0.3)
 Bone-targeted
  Any 455 (24.3) 163 (21.6) 32 (14.1) 176 (29.2)
  Zoledronic acid 330 (17.6) 120 (15.9) 20 (8.8) 126 (20.9)
  Denosumab 103 (5.5) 45 (6.0) 10 (4.4) 32 (5.3)
  Other 55 (2.9) 9 (1.2) 6 (2.6) 32 (5.3)
 Other 28 (1.5) 12 (1.6) 5 (2.2) 7 (1.2)
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groups, the most common reason for stopping treatment 
was disease progression (72.0%, 62.7%, and 24.3% of 
patients, respectively) (Supplementary Table S2). Death 
during treatment was reported in 6.9%, 11.9%, and 5.6% 
of patients in these treatment groups, respectively (Sup-
plementary Table S2).
3.3.3  Efficacy Outcomes
According to Kaplan–Meier estimates, the median (95% CI) 
time to progression was 9.7 (8.2–11.2), 9.8 (8.0–12.9), and 
7.4 (6.6–7.9), months for abiraterone, enzalutamide, and 
docetaxel, respectively (Fig. 1b, Table 4). The median (95% 
CI) OS was 27.4 (23.0–30.3), 26.1 (18.1–33.9), and 26.1 
(23.0–29.7) months in these treatment groups, respectively 
(Fig. 2b, Table 6).
3.4  Patients with Diabetes Mellitus
3.4.1  Baseline Characteristics
At baseline, 121 (16.0%), 47 (20.7%), and 100 (16.6%) 
patients had diabetes mellitus in the abiraterone, enzaluta-
mide, and docetaxel groups, respectively; in each treatment 
group, a lower proportion of those with diabetes mellitus 
had diabetes mellitus type 1 than diabetes mellitus type 2 
(71.9% vs. 28.1%, 76.6% vs. 23.4%, and 82.0% vs. 18.0% in 
the abiraterone, enzalutamide, and docetaxel groups, respec-
tively) (Table 1).
The median (range) time from initial diagnosis to study 
start was 5.7 (0–29), 4.0 (0–18), and 5.4 (1–20) years in the 
abiraterone, enzalutamide, and docetaxel groups, respec-
tively. Median (range) age at baseline was 77.0 (54–93), 
77.0 (62–91), and 69.0 (51–88) years, respectively (Sup-
plementary Table S4A). A Gleason score of 8–10 at diag-
nosis was reported in 47.7%, 55.8%, and 49.0% of these 
treatment groups, respectively (Supplementary Table S4A). 
The following important concomitant co-morbidity types 
were reported in the diabetes mellitus group for patients 
receiving abiraterone, enzalutamide, and docetaxel, respec-
tively: cardiovascular in 102 (84.3%), 36 (76.6%), and 85 
(85.0%) patients; neurologic in 13 (10.7%), 4 (8.5%), and 
12 (12.0%) patients; and renal in 10 (8.3%), 12 (25.5%), 
and 7 (7.0%) patients (Supplementary Table S4A). Details 
regarding treatment history at study inclusion are presented 
in Supplementary Table S4B.
3.4.2  Treatment Exposure
Median (95% CI) treatment duration was 11.5 (9.1–16.1), 
12.2 (8.2–17.5), and 4.3 (3.6–4.9) months in the abiraterone, 
enzalutamide, and docetaxel (typically 6–10 cycles) treat-
ment groups, respectively (Supplementary Table S1), which 
was similar to that in treatment groups for the overall pop-
ulation, in which docetaxel exposure was shorter than for 
abiraterone and enzalutamide. The most commonly reported 
reason for stopping treatment in abiraterone-, enzalutamide-, 
and docetaxel-treated patients was disease progression 
(66.3%, 57.9%, and 24.0%, respectively), followed by toxic-
ity (12.0%, 13.2%, and 19.0%, respectively) (Supplementary 
Table S2). Death during treatment was reported in 9.8%, 
18.4%, and 5.6% of patients, respectively (Supplementary 
Table S2).
3.4.3  Efficacy Outcomes
According to Kaplan–Meier estimates, the median (95% CI) 
time to progression was 12.0 (9.8–16.4), 10.3 (5.5–14.7), 
and 7.7 (5.7–9.0) months with abiraterone, enzalutamide, 
and docetaxel, respectively (Fig. 1c, Table 4). The median 
(95% CI) OS was 30.8 (21.7–not estimable [NE]), 27.1 
(14.7–NE), and 24.3 (16.1–29.0) months in these treatment 
groups, respectively (Fig. 2c, Table 6).
3.5  Patients with Visceral Metastases
3.5.1  Baseline Characteristics
Visceral metastases were reported in 59 patients (7.8%) in 
the abiraterone group, 16 (7.0%) in the enzalutamide group, 
and 88 (14.6%) in the docetaxel group. The small number 
of patients with visceral metastases in the enzalutamide 
group meant that meaningful analyses could not be per-
formed (Table 1). Details regarding patient demographics 
and disease and biological characteristics at study inclusion 
in patients with visceral metastases in the first-line treatment 
population and treatment history are presented in Supple-
mentary Tables S5A and S5B, respectively.
Table 3  Subsequent therapy for the first-line treatment population
a If treatment was interrupted for less than 30  days (abiraterone or 
enzalutamide) or 60 days (docetaxel or cabazitaxel), it was defined as 
continuing. Next therapy could be started immediately following ces-
sation of first-line treatment
n (%) Abiraterone Enzalutamide Docetaxel
First treatment set 754 227 602
Patients with a next 
 therapya
367 (48.7) 99 (43.6) 426 (70.8)
Therapy
 Abiraterone – 17 (17.2) 191 (44.8)
 Docetaxel 178 (48.5) 42 (42.4) –
 Enzalutamide 99 (27.0) – 116 (27.2)
 Cabazitaxel 4 (1.1) 2 (2.0) 74 (17.4)
 Other chemotherapy 10 (2.7) 1 (1.0) 8 (1.9)
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3.5.2  Treatment Exposure
The median (95% CI) treatment duration in abiraterone- 
and docetaxel-treated patients was 7.9 (5.5–10.9) and 4.3 
(3.5–5.1) months, respectively (Supplementary Table S1); 
the typical regimen for docetaxel treatment was 6–10 cycles. 
In this subgroup analysis, 10.4% and 11.6% of patients dis-
continued abiraterone and docetaxel treatment, respectively, 
because of toxicity; the most common reason was disease 
progression (70.8% and 26.7%), with 10.4% and 4.7% of 
patients dying (Supplementary Table S2). This compares 
to 7.4%, 72.8%, and 7.2%, for toxicity, disease progression, 
a b
c d
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Abi 754 505 325 231 162 120 83 51 0
Enz 227 145 102 74 51 30 15 6 0
Doc 602 381 161 50 23 15 8 5 0
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Enz 161 102 68 51 34 22 9 2 0
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Abi 121 83 61 39 30 22 12 7 0
Enz 47 28 19 12 9 6 4 0 0
Doc 100 63 24 5 2 2 1 1 0
Time to progression (months)



























Abi 59 34 14 11 9 8 6 4 0
Doc 88 54 29 10 7 6 4 3 0
Fig. 1  Time to progression in the first-line treatment population (a), and cardiovascular (b), diabetes mellitus (c), and visceral metastases sub-
groups (d). Abi abiraterone, Enz enzalutamide, Doc docetaxel
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and death, respectively, during treatment in the whole abi-
raterone treatment group and 14.2%, 27.0%, and 3.8% in the 
whole docetaxel group (Supplementary Table S2).
3.5.3  Efficacy Outcomes
In patients with visceral metastases, the median (95% CI) 
time to progression was 6.2 (4.8–8.1) and 7.8 (6.7–9.9) 
months with abiraterone and docetaxel, respectively (Fig. 1d, 
Table 4). The median (95% CI) OS was 17.40 (13.60–22.70) 
and 20.40 (15.10–26.10) months in abiraterone- and 
docetaxel-treated patients, respectively – shorter than in the 
respective overall patient populations (Fig. 2d, Table 6).
4  Discussion
The data in the PCR provide the first opportunity to evalu-
ate characteristics and outcomes of the largest cohort of 
patients with mCRPC receiving first-line treatment in 
Table 4  Time to progression in the first-line treatment population, including subgroups
CI confidence interval
a Criteria for disease progression were met if radiographic progression (progression date is date of the assessment); if no radiographic progres-
sion documented then clinical progression per investigator’s assessment (progression date is date of the patient visit) was used as the criterion. If 
no progression was documented using the criteria specified, then stopping medication because of progression (progression date is date that the 
treatment was stopped) was used as the criterion. New treatment started because of progression (progression date is date that the new treatment 
began) was used if previous medication was not stopped because of progression
Kaplan–Meier estimates (patients with no progression at end 
of Registry are censored)
Abiraterone Enzalutamide Docetaxel
First-line treatment population, N 754 227 602
Median time to  progressiona (95% CI), months 9.6 (8.4–10.8) 10.30 (8.9–13.0) 7.6 (7.0–8.0)
Patients with cardiovascular disease, N 504 161 351
Median time to  progressiona (95% CI), months 9.7 (8.2–11.2) 9.8 (8.0–12.9) 7.4 (6.6–7.9)
Patients with diabetes mellitus, N 121 47 100
Median time to  progressiona (95% CI), months 12.0 (9.8–16.4) 10.3 (5.5–14.7) 7.7 (5.7–9.0)
Patients with visceral metastases, N 59 – 88
Median time to  progressiona (95% CI), months 6.2 (4.8–8.1) – 7.8 (6.7–9.9)
Table 5  Unadjusteda and  adjustedb treatment effect for time to progression in the first-line treatment population
CI confidence interval
a The unadjusted analysis is a Cox proportional hazards model with treatment as only predictor
b The adjusted analysis is similar to the unadjusted but is based on the propensity score method; potential confounders are: age, log of time from 
diagnosis to castration resistance, log of time from diagnosis to metastasis, log of time from metastasis to study start, log alkaline phosphatase, 
log prostate-specific antigen, log hemoglobin, Gleason score, diabetes, use of strong analgesics, use of weak analgesics, cardiovascular disease, 
ECOG status 2–3, ECOG status unknown, prior radical prostatectomy, T class 3, T class 4, T class unknown, N class 1, N class unknown, M 
class 1, M class unknown, bone lesions 5–20, bone lesions > 20, and bone lesions unknown
Dependent variable Unadjusted/adjusted Comparison Number of 
observations
Hazard ratio (95% CI) p value
Unadjusted and adjusted treatment effect, time to progression, abiraterone vs. docetaxel (first line)
 Time to progression Unadjusted Abiraterone vs. docetaxel n = 1356 0.599 (0.529–0.678)  < 0.0001
 Time to progression Unadjusted Abiraterone vs. docetaxel n = 1049 0.597 (0.519–0.686)  < 0.0001
 Time to progression Adjusted Abiraterone vs. docetaxel n = 1049 0.685 (0.586–0.800)  < 0.0001
Unadjusted and adjusted treatment effect, time to progression, enzalutamide vs. docetaxel (first line)
 Time to progression Unadjusted Enzalutamide vs. docetaxel n = 829 0.548 (0.456–0.657)  < 0.0001
 Time to progression Unadjusted Enzalutamide vs. docetaxel n = 674 0.556 (0.455–0.678)  < 0.0001
 Time to progression Adjusted Enzalutamide vs. docetaxel n = 674 0.564 (0.455–0.698)  < 0.0001
Unadjusted and adjusted treatment effect, time to progression, abiraterone vs. enzalutamide (first line)
 Time to progression Unadjusted Abiraterone vs. enzalutamide n = 981 1.031 (0.867–1.226) 0.7302
 Time to progression Unadjusted Abiraterone vs. enzalutamide n = 751 1.009 (0.833–1.222) 0.9277
 Time to progression Adjusted Abiraterone vs. enzalutamide n = 751 1.040 (0.851–1.271) 0.7000
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the real-world setting. Notably, they encompass informa-
tion from patients from 16 countries included in the PCR 
between 2013 and 2016.
In this analysis of a real-world setting, patients treated 
with docetaxel as their first-line systemic mCRPC treat-
ment were younger than those treated with abiraterone or 
enzalutamide and had a shorter time from initial diagnosis 
to inclusion in the study. In addition, a higher proportion 
of patients in the docetaxel group had an Eastern Coop-
erative Oncology Group score of 1, visceral metastases, 
five or more bone metastases at baseline, and had de novo 
metastases at initial diagnosis. Biological parameters of 
prostate-specific antigen, lactate dehydrogenase, and alka-
line phosphatase levels also tended to be higher in patients 
a b
c d
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Fig. 2  Overall survival in the first-line treatment population (a), and cardiovascular (b), diabetes mellitus (c), and visceral metastases subgroups 
(d). Abi abiraterone, Enz enzalutamide, Doc docetaxel
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treated with docetaxel than in those who received the other 
treatment options. Together, these findings suggest that the 
patients treated with docetaxel had more advanced dis-
ease and poorer prognosis. These differences in baseline 
characteristics are not unexpected, given the observational 
methodology used to capture the treatment decisions made 
at the discretion of the treating physician. The clinical effi-
cacy and safety of docetaxel therapy in prostate cancer was 
achieved with a recommended dose of 75 mg/m2 every 
3 weeks over 10 cycles [10]; the median duration of doc-
etaxel treatment was approximately 4 months in the patient 
groups in the analysis. In contrast, the recommended dose 
of abiraterone was 1000 mg once daily [11], and the usual 
dose of enzalutamide is 160 mg taken at the same time 
once daily [12]. In general, treatment duration was not 
influenced by the presence of cardiovascular disease or 
diabetes mellitus in this study.
In this real-world analysis, which includes patients 
who are under-represented in prostate cancer clinical tri-
als, median OS of those enrolled in the PCR treated with 
first-line abiraterone, enzalutamide, or docetaxel as mCRPC 
therapy was 27.1, 27.1, or 27.9 months, respectively, com-
pared with a median OS of 34.7 months for patients treated 
with abiraterone acetate in the phase 3 COU-AA-302 study 
Table 6  Overall survival in the first-line treatment population, including subgroups
Patients alive at end of Registry are censored
CI confidence interval, N number of evaluable patients for each specific parameter, NE not estimable
Abiraterone Enzalutamide Docetaxel
First-line treatment population, N 754 227 602
Median overall survival (95% CI), months 27.1 (25.3–28.9) 27.1 (21.8–32.7) 27.9 (25.6–31.5)
Patients with cardiovascular disease, N 504 161 351
Median overall survival (95% CI), months 27.4 (23.0–30.3) 26.1 (18.1–33.9) 26.1 (23.0–29.7)
Patients with diabetes mellitus, N 121 47 100
Median overall survival (95% CI), months 30.8 (21.7–NE) 27.1 (14.7–NE) 24.3 (16.1–29.0)
Patients with visceral metastases, N 59 – 88
Median overall survival (95% CI), months 17.40 (13.60–22.70) – 20.40 (15.10–26.10)
Table 7  Unadjusteda and  adjustedb treatment effect for overall survival in the first-line treatment population
CI confidence interval
a The unadjusted analysis is a Cox proportional hazards model with treatment as only predictor
b The adjusted analysis is similar to the unadjusted, but is based on the propensity score method; potential confounders are: age, log of time from 
diagnosis to castration resistance, log of time from diagnosis to metastasis, log of time from metastasis to study start, log alkaline phosphatase, 
log prostate-specific antigen, log hemoglobin, Gleason score, diabetes, use of strong analgesics, use of weak analgesics, cardiovascular disease, 
ECOG status 2–3, ECOG status unknown, prior radical prostatectomy, T class 3, T class 4, T class unknown, N class 1, N class unknown, M 
class 1, M class unknown, bone lesions 5–20, bone lesions > 20, and bone lesions unknown
Dependent variable Unadjusted/adjusted Comparison Number of 
observations
Hazard ratio (95% CI) p value
Unadjusted and adjusted treatment effect, overall survival, abiraterone vs. docetaxel (first line)
 Overall survival Unadjusted Abiraterone vs. docetaxel n = 1356 1.035 (0.891–1.202) 0.6520
 Overall survival Unadjusted Abiraterone vs. docetaxel n = 1049 0.994 (0.841–1.176) 0.9462
 Overall survival Adjusted Abiraterone vs. docetaxel n = 1049 1.105 (0.920–1.328) 0.2843
Unadjusted and adjusted treatment effect, overall survival, enzalutamide vs. docetaxel (first line)
 Overall survival Unadjusted Enzalutamide vs. docetaxel n = 829 1.047 (0.843–1.301) 0.6763
 Overall survival Unadjusted Enzalutamide vs. docetaxel n = 674 1.064 (0.841–1.347) 0.6039
 Overall survival Adjusted Enzalutamide vs. docetaxel n = 674 1.075 (0.837–1.380) 0.5727
Unadjusted and adjusted treatment effect, overall survival, abiraterone vs. enzalutamide (first line)
 Overall survival Unadjusted Abiraterone vs. enzalutamide n = 981 0.983 (0.798–1.211) 0.8741
 Overall survival Unadjusted Abiraterone vs. enzalutamide n = 751 0.927 (0.737–1.165) 0.5147
 Overall survival Adjusted Abiraterone vs. enzalutamide n = 751 1.000 (0.788–1.270) 0.9986
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in asymptomatic or mildly symptomatic patients with 
chemotherapy-naive prostate cancer [13] and 18.9 months 
with three-times-weekly docetaxel in patients with meta-
static hormone-refractory prostate cancer in the phase 3 
TAX 327 study [9]. However, at the time of the TAX 327 
study, subsequent treatment options for mCRPC were lim-
ited, which may have influenced the OS rates in this study. 
In the FIRSTANA study, which evaluated cabazitaxel ver-
sus docetaxel treatment in chemotherapy-naïve patients with 
mCRPC, median OS was 24.3 months for docetaxel [14], 
which is similar to our findings. This study was initiated at 
a time when novel hormonal treatments were being used 
clinically to treat mCRPC after docetaxel.
In the phase 3 PREVAIL study of enzalutamide in 
patients with disease progression despite androgen-
deprivation therapy, median OS was longer, at 32.4 months 
[8]. However, the older age, presence of certain baseline 
characteristics (visceral metastases, ECOG status of 2 and 
above), and longer disease duration before treatment of 
patients in the PCR compared with those in the clinical tri-
als is likely to have affected treatment outcomes. Similarly, 
shorter OS in renal cancer has been reported for sunitinib in 
the non-clinical trial setting (18.7 months) compared with 
the first-line clinical setting (26.4 months) [15]. Treatment 
outcomes for mCRPC did not appear to be compromised 
by cardiovascular disease and diabetes mellitus in the pre-
sent study; however, in patients with visceral metastases, 
OS was approximately 7 months shorter than in the overall 
population.
Data from the PCR provide information on patient sub-
groups that are poorly represented in pivotal trials. Nota-
bly, the PCR provides information on many patients with 
cardiovascular co-morbidities and patients with both car-
diovascular and diabetic co-morbidities. The PCR does not 
provide information on the severity of the co-morbidities 
or whether patients’ conditions related to co-morbidities at 
baseline were well controlled by concomitant medications 
at baseline, which may affect their outcomes. Other than dis-
ease progression, toxicity was the next most common reason 
for stopping systemic mCRPC treatment in patients with 
cardiovascular disease (8.9% and 16.7% of patients treated 
with abiraterone and enzalutamide, respectively). This was 
also a reason for stopping treatment in patients with diabetes 
mellitus (12.0% and 13.2% stopped abiraterone and enzalu-
tamide, respectively). In addition, the higher incidence of 
treatment-limiting toxicity in patients with diabetes mellitus 
compared with the overall population and in patients with 
cardiovascular disease suggests that extra care should be 
taken in treating these men.
This study benefits from a number of strengths, includ-
ing robust monitoring providing clinical trial-level qual-
ity data, the size and scope of the Registry, allowing for a 
large amount of data to be collected, inclusion of patient 
subgroups under-represented in clinical trials, and a dura-
tion that allows mature data to be collected during a period 
that has seen a number of advances in mCRPC treatment. 
Furthermore, this is the largest data set on abiraterone treat-
ment in patients with CRPC with visceral metastases in the 
real-world setting. However, several limitations exist. This 
is an observational study, and there is no randomization to 
allow direct treatment comparisons. In addition, because 
treatment followed clinical practice, duration of exposure 
varied between treatments based on treatment cycles. Thus, 
the results for duration of treatment and reason for stopping 
treatment or number of deaths during the treatment period 
cannot be compared between docetaxel and abiraterone or 
docetaxel and enzalutamide because of the possible influ-
ence of the dosing regimens of the drugs; docetaxel has a 
shorter dosing regimen, being administered in 6–10 cycles, 
compared with the daily regimens of abiraterone acetate and 
enzalutamide, which are administered until the point of dis-
ease progression. Data were also collected at routine clinical 
visits, which may not have occurred at regular intervals for 
all patients. The commercial availability of the treatments 
in participating countries, different treatment practices and 
settings, and timing of enrollment should also be taken into 
consideration; the treatment options available in each coun-
try of the PCR varied according to availability of different 
drugs, which may have influenced findings.
5  Conclusions
This analysis shows for the first time the effectiveness in par-
allel of three major treatments in first-line mCRPC therapy: 
abiraterone, enzalutamide, and docetaxel. More importantly, 
the efficacy of these treatments was similar among subpopu-
lations of patients with co-morbidities such as cardiovas-
cular disease or diabetes mellitus compared with the wider 
patient group. For the subpopulation of patients with vis-
ceral metastases, outcomes were as expected considering the 
poor prognosis for this subgroup. This real-world analysis of 
long-term efficacy outcomes of patients in the PCR provides 
meaningful data to support physicians in managing different 
patient groups with mCRPC, which is associated with poor 
prognosis and mortality. Because the PCR includes patients 
from several countries and represents real-world practice, 
these results apply to most men with mCRPC.
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